Topical Delivery of a Naproxen-Dithranol Co-drug: In Vitro Skin Penetration, Permeation, and Staining
- 446 Downloads
This work probed the topical delivery and skin-staining properties of a novel co-drug, naproxyl-dithranol (Nap-DTH), which comprises anti-inflammatory (naproxen) and anti-proliferative (dithranol) moieties.
Freshly excised, full-thickness porcine ear skin was dosed with saturated solutions of the compounds. After 24 h, the skin was recovered and used to prepare comparative depth profiles by the tape-stripping technique and to examine the extent of skin staining.
Depth profiles showed that Nap-DTH led to a 5-fold increase in drug retention in the skin compared to dithranol. The application of Nap-DTH also demonstrated improved stability, resulting in lower levels of dithranol degradation products in the skin. Furthermore, significantly less naproxen from hydrolysed Nap-DTH permeated into the receptor phase compared to naproxen when applied alone (0.08 ± 0.03 nmol cm-² and 180 ± 60 nmol cm-², respectively). Moreover, the reduced staining of the skin was very apparent for Nap-DTH compared to dithranol.
Topical delivery of Nap-DTH not only improves the delivery of naproxen and dithranol, but also reduces unwanted effects of the parent moieties, in particular the skin staining, which is a major issue concerning the use of dithranol.
KEY WORDSanti-proliferative co-drug ester hydrolysis prodrug psoriasis
limit of detection
The authors would like to acknowledge the financial support from Stiefel Laboratories, UK.
Conflict of interest
- 1.National Psoriasis Foundation. About psoriasis: statistics. http://www.psoriasis.org/about/stats/ (accessed 19 May 2008).
- 9.McGill A, Frank A, Emmett N, Leech SN, Turnbull DM, Birch-Machin MA, Reynolds NJ. The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J. 2005;04-2664.Google Scholar
- 18.Lau WM. Improved topical therapeutic systems based on co-drugs. Welsh School of Pharmacy. PhD thesis. 2008.Google Scholar
- 19.International Conference of Harmonisation. Guidance for industry: Q1A(R2) stability testing of new drug substances and products. www.fda.gov/CbER/gdlns/ichstab.htm (accessed 12 Apr 2008).
- 23.Simonand GA, Maibach HI. The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations—an overview. Skin Pharmacol Appl Skin Physiol. 2000;13:229–34.Google Scholar
- 24.Meyer W, Kacza J, Zschemisch N-H, Godynicki S, Seeger J. Observations on the actual structural conditions in the stratum superficiale dermidis of porcine ear skin, with special reference to its use as model for human skin. Annals of Anatomy—Anatomischer Anzeiger. 2007;189:143–56.CrossRefGoogle Scholar
- 28.Leung DYM, Szfler SJ, Noman PS, Apter A, Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol. 2003;111:1154–68.Google Scholar
- 30.The British Pharmacopoeia Commission. British Pharmacopoeia 2008 The Stationery Office, London, 2007.Google Scholar
- 38.Das M, Bickers DR, Mukhtar H. Epidermis: the major site of cutaneous benzo(a)pyrene and benzo(a)pyrene 7, 8-diol metabolism in neonatal BALB/c mice. Drug Metab Disposition. 1986;14:637–42.Google Scholar